Navigation Links
The Burnham buzz
Date:12/8/2008

Enzyme May Hold the Key to Muscular Dystrophy

A mutation in the gene coding the protein dystrophin has long been known to be associated with muscular dystrophy, but the role the protein plays in the disease was unknown. Lorenzo Puri, M.D., Ph.D. and colleagues have discovered that the dystrophin mutation causes an increase in the amount of the histone deacetylase enzyme, HDAC2. Increased HDAC2 activity alters the gene expression profile in the diseased muscle cells compared to normal muscle cells. By inhibiting HDAC2 with small molecule compounds or RNA interference, Dr. Lorenzo was able to return the muscle cells with the dystrophin mutation to normal histology and function. This advancement may lead to novel therapies for muscular dystrophy.

Microscopic Race for New Cures

Jeff Price, M.D., Ph.D. has created a next generation robotic microscope which can be used for high-throughput cellular image analysis to discover new potential drugs. The novel instrumentation utilizes chromatic aberrationthe difference in focus between different colors of light in optical systemsto simplify and speed auto-focusing of the microscope via digital color cameras. This advancement will increase screening from the 20,000 -- 40,000 compounds possible per day with existing technology, to more than 100,000 screens per day, a five-fold increase in productivity.

Nanoworms Make Tumors Squirm

Nano-scale worms made out of iron oxide (rust) may be the next big breakthrough in cancer treatment. Erkki Ruoslahti, M.D., Ph.D., along with collaborators at the University of California, San Diego and the Massachusetts Institute of Technology, has shown that iron oxide nanoworms can bind to tumors when coated with tumor-homing peptides. The team is now attempting to design nanoparticles that will seek out tumors in the body, send a diagnostic signal and release a drug at the site of the tumor in a controlled manner.

What's in Fashion: Designer Drugs to Block Breast Cancer

Gregory Roth, Ph.D., and colleagues have determined that a biologically active molecule called a chemokine promotes the spread of tumors, particularly in breast cancer. Dr. Roth believes that compounds that block the chemokine may be potential cancer therapies. However, existing small molecules that bind to chemokines only bind weakly, making them poor drug candidates. Dr. Roth and a team of Burnham chemists are working to custom-design molecules that bind tightly to the chemokine, hoping to block its activity and stop the spread of tumors.

Choking Out Cancer

Ze'ev Ronai, Ph.D. is trying to kill off cancer by choking it. When tumors are deprived of oxygen, they activate a transcription factor called HIF-1a that helps the tumor compensate and survive. Inhibiting HIF-1a has been hypothesized to be a means of defeating cancer, as tumors eventually experience oxygen deprivation due to insufficient blood flow to the tumor. Dr. Ronai's laboratory has demonstrated proof of this concept by inhibiting PHD3, a regulator of HIF-1a. Binding of short protein fragments to PHD3 results in HIF-1a degradation and halts growth of metastatic tumors in mice. Dr. Ronai's team is now investigating how small molecule compounds might accomplish the same thing.


'/>"/>

Contact: Josh Baxt
jbaxt@burnham.org
858-795-5236
Burnham Institute
Source:Eurekalert

Related biology news :

1. Burnham researchers turn cancer friend into cancer foe
2. Burnham researcher awarded $8 million grant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
(Date:5/9/2016)... 9, 2016 Elevay is currently ... expanding freedom for high net worth professionals seeking travel ... globally connected world, there is still no substitute for ... duplicate sealing your deal with a firm handshake. This ... taking advantage of citizenship via investment programs like those ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... Parallel ... clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module ... circle with the physician and clinical trial team. , Using the CONSULT module, patients ...
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, ... second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical ... eBook by providing practical tips, tools, and strategies for clinical researchers. , “The ...
Breaking Biology Technology: